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Abstract
Background: Multiple subtypes of avian influenza viruses have crossed the species barrier to infect humans and
have the potential to cause a pandemic. Therefore, new influenza vaccines to prevent the co-existence of multiple
subtypes within a host and cross-species transmission of influenza are urgently needed.
Methods: Here we report a multi-epitope DNA vaccine targeted towards multiple subtypes of the influenza virus.
The protective hemagglutinin (HA) antigens from H5/H7/H9 subtypes were screened for MHC II class-restricted
epitopes overlapping with predicted B cell epitopes. We then constructed a DNA plasmid vaccine, pV-H3-EHA-H1,
based on HA antigens from human influenza H3/H1 subtypes combined with the H5/H7/H9 subtype Th/B epitope
box.
Results: Epitope-specific IFN-g ELISpot responses were significantly higher in the multi-epitope DNA group than in
other vaccine and control groups (P < 0.05). The multi-epitope group significantly enhanced Th2 cell responses as
determined by cytokine assays. The survival rate of mice given the multi-epitope vaccine was the highest among
the vaccine groups, but it was not significantly different compared to those given single antigen expressing pV-
H1HA1 vaccine and dual antigen expressing pV-H3-H1 vaccine (P > 0.05). No measurable virus titers were detected
in the lungs of the multi-epitope immunized group. The unique multi-epitope DNA vaccine enhanced virus-specific
antibody and cellular immunity as well as conferred complete protection against lethal challenge with A/New
Caledonia/20/99 (H1N1) influenza strain in mice.
Conclusions: This approach may be a promising strategy for developing a universal influenza vaccine to prevent
multiple subtypes of influenza virus and to induce long-term protective immune against cross-species transmission.
Background
Over the years, influenza has become a serious public
health problem. With the potential for sudden out-
breaks, rapid spread, and high incidence of complica-
tions, the prevalence of influenza infections has caused
tremendous loss of human life and material resources
[1,2]. Thus, it is important to develop new approaches
towards preventing seasonal infections as well as poten-
tial pandemics of influenza.
Based on their internal protein antigens, different
influenza viruses can be divided into 3 types: A, B, or C.
The surface antigens, hemagglutinin (HA) and neurami-
nidase (NA) are also used to identify different subtypes.
At present, the prevalent human influenza viruses are
the type A H3/H1 and type B viruses. However, in
recent years, multiple subtypes (H5/H7/H9) of the avian
influenza virus (AIV) have been able to cross the species
barrier to infect humans [3,4]. Around the world, the
highly pathogenic avian influenza virus subtype H5N1
has caused infectious outbreaks in various human popu-
lations [5]. Influenza vaccines based on the conventional
subtypes of each species have been unable to effectively
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provide long-term protection against more than one
s u b t y p eo fi n f l u e n z ah a sb e c o m eah o tt o p i ci nv a c c i n e
development. However, due to the rapidly changing
influenza virus or the phenomena of “antigenic shift”
and “antigenic drift”, developing a vaccine that can pro-
tect against all possible circulating viruses is extremely
challenging.
Immunogenic epitopes in an antigen is determined by
the major histocompatibility complex (MHC) class I for
cytotoxic T cell lymhocytes (CTL) and MHC class II for
T helper (Th) cells. These polymorphic MHC molecules
present short peptides that are processed after an exo-
genous antigen (such as a viral protein) is taken up by
antigen presenting cells (APC) such as macrophages and
dendritic cells. These APC then “present” the peptide to
the immune cells that recognize the MHC/peptide com-
plex via the T cell receptor (TCR) or B cell receptor
(BCR). Theoretically, given any set of MHC II restricted
peptides presented to the Th cells, the optimal sequence
would be those that could also stimulate B cells to pro-
duce antibodies since activation of antigen-specific Th
cells also promote antibody production. By understand-
ing the specific epitopes from pathogens that can stimu-
late optimal immune responses, we will better
understand how to tailor vaccines to a specific popula-
tion and/or pathogen.
Indeed, many studies have shown the efficacy of pep-
tide-based vaccines in animal models [6], as well as in
clinical studies against infectious diseases, including
malaria [7,8], hepatitis B [9] and HIV-1 [10,11]. Develop-
ment of an epitope-based vaccine for influenza may also
be a useful strategy to overcoming the challenge of indu-
cing a specific immune response against this constantly
evolving virus. CTL epitopes mediate cytolytic effects on
infected cells and induce inflammatory factors during
viral clearance, while B cell epitopes can induce protec-
tive antibody-mediated humoral immune responses. Th
epitopes can activate CD4+ T cells to carry out important
immune regulatory functions, and the identification of
specific epitopes derived from influenza virus has signifi-
cantly advanced the development of peptide-based vac-
cines [12-15]. Improved understanding of the molecular
basis of antigen recognition and human leukocyte antigen
(HLA) binding motifs has allowed the development of
rationally designed vaccines based on motifs predicted to
bind to human class I or class II MHC. Therefore, identi-
fication of the corresponding functional influenza epi-
topes will have important theoretical and practical value
in studies on immunity against virus infection and on
vaccine development.
Presently, standard inactivated vaccines based on one
or a few circulating strains are mainly utilized for pre-
vention of influenza infection, but they cannot
effectively deal with the current trend of increasing var-
iations of the circulating viruses. A new influenza vac-
cine that can afford long-term and cross-species
protection against multiple subtypes of influenza is
imperative. Developing DNA vaccines that can stimulate
both humoral and cellular immunity is a promising area
of research. In particular, a multi-epitope DNA vaccine
which expresses antigen genes in tandem can efficiently
present the defined protective epitopes to stimulate the
immune system while eliminating non-essential compo-
nents or potential toxic fragments of traditional inacti-
vated vaccines. Additionally, the development of such
multivalent vaccines can be combined with other vac-
cine antigens to enhance immunogenicity. The advan-
tage of combination vaccines is that they can potentially
provide broader coverage to protect against rapidly
mutating viruses such as influenza.
We report here the generation and evaluation of the
immunogenicity of a DNA vaccine expressing HA based
on human influenza H3/H1 combined with a class II
MHC multi-epitope antigen (hereafter referred to as the
“multi-epitope” vaccine). The vaccine was evaluated for
induction of humoral and cellular immune responses in
a mice model as well as for the protective efficacy
against lethal H1N1 subtype virus challenge. We
expected the vaccine targeted towards human influenza
subtype H3 and H1 to provide total protection against
these strains while at the same time achieving some
level of protective efficacy against other influenza sub-
types. This approach may be effective against rapidly
mutating influenza and provide longer-term protection
while laying the foundation for development of a new
universal influenza vaccine.
Materials and methods
Mice, viruses and cells
Female BALB/c mice (6-8 weeks old) were used for
immunization and challenge studies. All mice were
maintained with free access to sterile food and water.
A/New Caledonia/20/99 influenza virus (H1N1) (Gen-
Bank CY033622) and A/Wisconsin/67/2005 (H3N2)
strains were stored in the laboratory. Virus stocks were
propagated in the allantoic cavity of 10-day-old embryo-
nated chicken eggs for 48 h at 37°C. The viruses were
titrated by the Reed and Muench method to determine
the median lethal dose (LD50). Baby hamster kidney
(BHK-21) cells were used for transient expression
experiments. All experiments with influenza viruses
were conducted under BSL-3 containment, including
work in animals.
Design of epitopes box and synthetic peptides
T h eH Ag e n es e q u e n c e so ft h ei n f l u e n z aH 5 ,H 7 ,H 9
subtypes which have crossed species barriers to infect
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from NCBI http://www.ncbi.nlm.nih.gov with the follow-
ing main reference sequence accession numbers, res-
pectively: ISDN125873 (A/Indonesia/5/05(H5N1)),
AAR02636 [A/Netherlands/127/03(H7N7)], and
DQ997437 [A/swine/Shandong/nc/2005(H9N2)]. MHC
II restricted epitopes were predicted bioinformatically by
the network server SYFPEITHI and Multipre, and B cell
epitopes were predicted using the network server
BCEPRED http://www.imtech.res.in/raghava/bcepred/ or
the Biomolecule simulation software Insight II (Accelrys,
2005). Th cell epitope predictions were based upon their
cumulative binding affinity to six of the most common
HLA-DRß1 alleles (DRß1*0101, DRß1*0301, DRß1*0401,
DRß1*0701, DRß1*1101, and DRß1*1501). The network
server BCEPRED was used for linear B cell epitope pre-
diction which screens sequences based on hydrophilicity,
accessibility, flexibility, antigenicity, polarity, and
exposed surface residues. The Th epitope prediction was
narrowed down to include as much as possible the epi-
topes which overlapped with the predicted B cell epi-
topes in order to obtain epitopes with dual functions of
stimulating both T and B cells.
The Th/B cell epitope box was designed with
“GPGPG” linkers between each epitope in order to
reduce interference between epitopes and to ensure the
proper processing and function of each epitope indepen-
dently. The “KK” linker was also added to prevent the
epitopes between subtypes from “splitting”,t h a ti s ,t o
avoid generation of new junctional epitopes [16,17].
Based on the design of the epitope box, the nucleotide
sequences were codon-optimized and the peptides
synthesized accordingly (Xu Guan Biological Engineer-
ing Co., Ltd. Shanghai, PR China). Peptides were dis-
solved in 20% DMSO and frozen at -80°C until use.
Construction of plasmids
The HA genes of influenza A/New Caledonia/20/99
[H1N1] and A/Wisconsin/67/2005 [H3N2] were
obtained by RT-PCR amplification of the isolated RNA.
The H3HA, H1HA1 and the epitope box (termed EHA)
sequences were inserted into the pMD18-T vector after
addition of restriction sites Nhe I/Hind III, Cla I, Xho I,
Cla I/Xho Ia n dHind III/Xho I, respectively, to yield
pMD18-H3HA, pMD18-H1HA1 and pMD18-EHA. A
eukaryotic expression vector, pVAX1 (Invitrogen, Carls-
bad, CA, USA) was used to construct the following
DNA vaccine vectors: pV-H3HA, pV-H1HA1, pV-H3-
H1 and pV-H3-EHA-H1. The four DNA constructs
were sequenced to confirm cloning accuracy before
amplification in Escherichia coli JM109 and purification
using endotoxin-free kits (QIAGEN, Valencia, CA). The
final DNA preparations were resuspended in sterile sal-
ine solution and stored at -20°C until further use.
Indirect immunofluorescence assay
BHK-21 cells were transfected with purified DNA from
pV-H3HA, pV-H1HA1, pV-H3-H1, pV-H3-EHA-H1
and pVAX1 using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s protocol. In brief, cell
monolayers were grown on glass coverslips in a 6-well
plate and were then transfected with the plasmid DNA
(10 μg/well). At 48 h after transfection, the cells were
fixed with 0.05% glutaraldehyde and permeabilized with
0.5% Triton X-100 in phosphate-buffered saline (PBS),
followed by incubation with rabbit anti-HA of A/New
Caledonia/20/99 (H1N1), A/Wisconsin/67/2005 (H3N2),
A/Indonesia/5/05(H5N1), A/Netherlands/127/03(H7N7),
A/swine/Shandong/nc/2005(H9N2) polyclonal antibody
[1:200 in poly(butylene succinate-co-terephthalate)
(PBST)] for 1 h at 37°C. Fluorescein isothiocyanate
(FITC)-conjugated goat anti-rabbit IgG antibodies [in
PBS/bovine serum albumin (BSA)] were added and then
incubated for 1 h at room temperature. After mounting
the samples, fluorescence images were scanned using an
Olympus microscope (BX51; Olympus, Japan).
Immunization and virus challenge
In challenge experiments, four DNA vaccine groups and
an empty vector pVAX1 control group of female Balb/c
mice (n = 15) were immunized intramuscularly (IM,
each with 100 μg of plasmid DNA in 100 μLo fP B S
[pH 7.4] in the two hind quadriceps). The immunization
schedule consisted of 2 administrations with a 3-week
interval, and bleeding was performed at 0, 1, 2, 3, 4 and
5 weeks after immunization for determination of anti-
body titers. To assess the efficacy of the cross-protective
immunity of the 2 vaccine doses against lethal challenge
2 weeks after the second immunization, the immunized
mice were anesthetized and intranasally challenged with
10 LD50 (50% lethal doses) of the A/New Caledonia/20/
99 H1N1 virus in a final volume of 100 μL. The chal-
lenge experiments were performed in a biosafety level 3
(BSL3) facility (Military Veterinary Institute, Changchun,
PR China).
Viral lung titer measurements
To determine tissue viral titers, the lungs of surviving
mice challenged with H1N1 were collected and homoge-
nized by mechanical disruption. The viral titers were
determined by plaque formation assay performed in
MDCK cells in the presence of trypsin as previously
described [18,19].
Serum cytokine assays
A pre-coated enzyme-linked immunosorbent assay
(ELISA) kit was used (Dakewe Biotech, PR China) to
determine the cytokines levels of interferon (IFN)-g and
interleukin (IL)-4 in the immunized the mice according
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(100 μl) from different groups of mice were tested in
duplicate. After 36 h of incubation with the standards
and samples, the plates were washed, followed by addi-
tion of 50 μl of the Streptavidin-HRP solution. The plates
were incubated at 37°C for 60 min before washing again
for at least five times, with a 1-2 min interval in between
each wash. The diluted substrate was added at 50 μlp e r
well and incubated at 37°C for 15 min. Finally, 50 μlo f
stop solution were added per well to terminate the reac-
tion. Absorbance values were measured at 450 nm. Stan-
dard curves were drawn according to the instructions of
the kits. The cytokines levels in the samples were calcu-
lated accordingly, expressed as ΔX ± SD, and differences
between groups were analyzed statistically.
IFN- g ELISpot assays
The frequencies of IFN-g secreting splenocytes were
analyzed using a commercially available mouse IFN-g
pre-coated ELISpot assay according to the instructions
of the manufacturer (Dakewe Biotech, PR China).
Lymphocytes from the spleen were removed aseptically
10 days after a boost immunization, and a single cell
suspension (10
6 cells/well) was prepared and stimulated
with 20 μg/ml of the inactivated whole virus antigen
preparations of A/New Caledonia/20/99 (H1N1) and
A/Wisconsin/67/2005 (H3N2) or the following HA anti-
gen peptides (20 μg/ml) of A/Indonesia/5/05(H5N1), A/
Netherlands/127/03(H7N7), and A/swine/Shandong/nc/
2005(H9N2): H5HA141-155,H 5 H A 206-223,H 5 H A 302-316,
H7HA165-181,H 7 H A 255-269,H 7 H A 182-196,H 9 H A 123-140,
H9HA73-90, H9HA37-54. The plates were placed in a CO2
incubator at 37°C. The following day, the splenocytes
were discarded, and the plates were extensively washed
with pre-chilled PBS. IFN-g spots were detected by a
biotinylated anti-mouse IFN-g specific antibody, fol-
lowed by addition of streptavidin-horseradish peroxidase
(HRP) and development with 3-amino-9-ethylcarbazole
(AEC) substrate solution. The spots were counted using
an automated ELISpot reader. The results were
expressed as the number of spot-forming cells (SFC)/10
6
spleen cells. P-values were calculated using a permuta-
tion test stratified for the experiment.
Antibody detection
Virus antigen specific serum antibodies were detected by
ELISA. The inactivated H1N1 and H3N2 virus (50 ng/
well) or standard antigens of H5, H7 and H9 subtype
were coated overnight in 96-well plates (Costar,
Cambridge, MA, USA). Following blocking of non-speci-
fic binding, the serum samples were diluted 100 times in
PBS containing 0.5% (wt/vol) gelatin, 0.15% Tween 20,
and 4% calf serum (ELISA diluent) and applied in dupli-
cate wells for a 1 h incubation at 37°C. The plates were
washed five times with PBS and then reacted with a
1:2000 dilution of HRP-labeled goat anti-mouse IgG
(Zhongshan Goldenbridge Biotech) for 1 h at 37°C.
After another five washes with PBS, the substrate was
added (10 mg ortho-phenylenediamine [OPD] + 20 mL
0.015% hydrogen peroxide in phosphate/citrate buffer).
After incubation for 15 min at 37°C, the reactions were
terminated with 2N H2SO4. Subsequently, the absor-
b a n c ev a l u e sw e r ed e t e r m i n e da t4 9 2n mu s i n gaS u n -
rise automated plate spectrophotometer and analyzed
with Microsoft Excel 2007 for Windows. P-values were
calculated to detect significant differences among the
groups.
Statistical analysis
The Lifetest procedure using the Kaplan-Meyer method
and log rank test were applied for survival analyses
between study groups (H1N1 survival study). All tests
applied were two-tailed, and P-values of 5% or less were
considered statistically significant. The data was ana-
lyzed using the SPSS Version 16.0 software.
Results
Selection of epitopes
SYFPEITHI and Multipre were used in different algo-
rithms to predict Th epitopes. BCEPRED is an improved
linear B cell epitope prediction method that utilizes
multi-parameter analysis to predict potential B cell epi-
topes. Comprehensive analyses of both Th and B cell
epitopes were performed to obtain a set of epitopes in
which the predicted Th epitopes would also contain
potential B cell epitopes. The selected epitope regions
were re-evaluated for their spatial conformation and
specificity to determine the final epitopes (Figure 1A-C).
A final total of 9 Th and B cell epitopes were obtained
for the H5, H7 and H9 subtypes of influenza (Table 1),
and the corresponding peptides were synthesized with
BSA conjugated at the C terminus.
Construction of the expression plasmid and
immunogenicity assay
Before testing the immunogenicity of the vaccines, the
four DNA vaccine constructs (Figure 2) were confirmed
by sequencing. Protein expression from these constructs
were also verified by transfection of pV-H3HA, pV-
H1HA1, pV-H3-H1, pV-H3-EHA-H1 and pVAX1
(empty vector control) in BHK-21 cells, and the HA
antigens and epitopes were detected by an immuno-
fluorescence assay with HA anti-serum at 48 h post-
transfection (Figure 3). The results indicated that the
pV-H3HA, pV-H1HA1, pV-H3-H1, pV-H3-EHA-H1
plasmids could successfully expressed their correspond-
ing proteins and multi-epitopes, thereby validating the
use of the plasmids in subsequent experiments.
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Fourteen days after the boost immunization, the sera were
collected and analyzed for IFN-g and IL-4 levels levels by
ELISA (Figure 4A, B). The order of the IFN-g levels
detected in the immune sera were as follows: multi-epi-
tope immune group (pV-H3-EHA-H1, 463) > two-subtype
co-expression immune group (pV-H3-H1, 435) > H1
group (pV-H1HA1, 410) > H3 group (pV-H3HA, 398) >
pVAX1 control group (201). The serum IFN-g levels of
the immunized groups were significantly higher (P < 0.01)
than that of the control group, indicating that all of the
vaccines tested effectively stimulated Th1 type responses.
The multi-epitope group displayed the highest level of
IFN-g secretion, although the difference was not signifi-
cant compared with the other 3 groups (P > 0.05).
As for the detection of IL-4 levels in the immune sera,
the order was determined as follows: multi-epitopes
immune group (pV-H3-EHA-H1, 654) > two-subtype co-
expression immune group (pV-H3-H1, 431) > H3
immune group (pV-H3HA, 383) > H1 immune group
(pV-H1HA1, 315) > pVAX1 control group (188). The IL-
4 levels of the immune groups were also significantly
higher (P < 0.01) than that of the pVAX1 control group.
The IL-4 levels in the serum of the multi-epitopes group
were significantly higher than that of the other immune
groups (P < 0.05), indicating that the immunized groups
had significantly enhanced Th2 cell function. Combined
with the analysis of IFN-g levels above, these findings
demonstrated that the multi-epitope vaccine induced the
greatest levels of vaccine specific immune responses in
mice, and the use of these epitopes tended to produce
Th2 cytokines and promoted humoral immunity.
Figure 1 Insight II software simulation of trimeric HA molecules on the surface of the virus. The yellow area indicates the candidate
epitope that mainly consists of random coiled structures and turns and may contain a small portion of a b-sheet structure or a-helix structure.
Most of the candidate epitopes are exposed on the surface. (A) Simulated conformation of H5 HA candidate epitopes 1. HA141~155 2. HA206~223
3. HA302~316 (B) Simulated conformation of H7 HA candidate epitopes. 1. HA165~181 2. HA182~196 3. HA255~269. (C) Simulated conformation of H9
HA candidate epitopes. 1. HA37~54 2. HA73~90 3. HA123~140.
Table 1 Predicted Th and B cell epitopes included in the
multi-epitope vaccine
Epitope Amino acid sequences
H5HA141-155 PSFFRNVVWLIKKNS
H5HA206-223 TLNQRLVPKIATRSKVNG
H5HA302-316 CPKYVKSNRLVLATG
H7HA165-181 DPALIIWGIHHSGSTA
H7HA255-269 SMGIQSDVQVDANCE
H7HA182-196 QTKLYGSGSKLITVG
H9HA123-140 NVSYSGTSKACSDSFYRS
H9HA73-90 GGKWSYIVERPSAVNGMC
H9HA37-54 HNGMLCATNLGHPLILNT
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plasmid immunized mice
To evaluate the cellular responses to vaccination, sple-
nocytes were harvested from five immunized mice
from each group at 35 days after vaccination. Repre-
sentative data from three repeated ELISpot assays
detecting IFN-g secretion from virus or peptide stimu-
lated splenocytes are shown in Figure 5. Significant
IFN-g responses were observed in the immunized
g r o u pa sc o m p a r e dt oc e l l sfrom non-immunized mice
following in vitro incubation with whole inactivated
viruses [influenza virus A/Wisconsin/67/2005 (H3N2)
and influenza virus A/New Caledonia/20/99 (H1N1)]
(Figure 5A). The multi-epitope DNA group (pV-H3-
EHA-H1) produced the most spots under the stimula-
tions described above, but the differences were not sig-
nificant (P > 0.05) compared to other immunized
groups. However, the multi-epitope DNA group did
have significantly (P < 0.05) higher levels of IFN-g
secretion than the other groups in response to peptide
antigens (Figure 5B).
Antibody responses induced in DNA vaccine
immunized mice
In evaluating the development of virus-specific IgG
against the H3 and H1 subtypes of influenza by ELISA
(Figure 6A, B), the antibodies were detectable from the
first week after immunization, rising after the second
week, and then decreased slightly from the third week
after a rapid increase to its peak. At 35 days post-inocu-
lation (DPI), virus specific antibody levels in all immuni-
zation groups were significantly higher than that in the
control group (P < 0.01), but the levels of the different
vaccine groups were not significantly different from
each other (P > 0.05). That is, the IgG antibody levels
induced were equivalent between the multi-epitope vac-
cine group (pVAX1-H3-EHA-H1), the single antigen
expressing groups (pV-H3HA and pV-H1HA1) and the
dual antigen expressing group (pV-H3-H1).
From the analysis of H5, H7, H9 subtypes of influenza
virus-specific IgG antibodies (Figure 6C), the various
vaccine groups generated significantly higher antibody
levels than the control group in the ELISA (P < 0.01) at
35 DPI. Furthermore, the Th/B multi-epitope group
(pV-H3-EHA-H1) had significantly higher H5, H7 and
H9 subtype IgG levels than the other immunized groups
(pV-H3HA, pV-H1HA1 and pV-H3-H1), suggesting that
the selected epitopes could effectively stimulate virus-
specific antibodies. The highest antibody levels detected
by ELISA were against the H5 epitopes, suggesting that
this vaccine would theoretically be more effective against
this virus subtype in mice.
Figure 2 Schematic diagram of the four DNA vaccine constructs. (A) pV-H3HA, (B) pV-H1HA1, (C) pV-H3-H1, (D) pV-H3-EHA-H1. The Kozak
sequence was added before the ORF to promote protein expression. The MHC class II-restricted epitope box, EHA, was inserted into the co-
expression plasmid pV-H3-H1. A flexible linker (G4S)3 was added to allow effective fusion gene expression and promote the correct folding of
expressed proteins. The autocleaving 2A protein linker from foot and mouth disease virus was also added to allow cleavage of the fusion
protein after expression.
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influenza H1N1
To test the efficacy of the vaccines, BALB/c mice (6 weeks)
were immunized IM with 200 μg of each vaccine and chal-
lenged with 10 LD50 of A/New Caledonia/20/99 (H1N1)
influenza strain. Their survival rates were monitored for
the following 14 days. The mice began to show clinical
signs or death from influenza infection on day 5 post-chal-
lenge. Figure 6 shows the survival curve following these
immunizations, and the final survival rates of the pV-
H1HA1, pV-H3-H1, and pV-H3-EHA-H1 immunized
mice were 90%, 80%, and 100%, which were significantly
higher (P < 0.01) than that of the pV-H3HA and pVAX1
control groups (20% and 0%, respectively; Figure 7). Immu-
nization with the multi-epitope vaccine resulted in com-
plete protection against the lethal dose virus challenge,
which was better than the single expression (pV-H1HA1)
and co-expression immunized group (pV-H3-H1).
Lung viral titers
The lungs were harvested from mice which survived the
viral challenge, and viral titers were determined by
plaque formation assays in MDCK cells. Because almost
all the mice which received the pVAX1 control and pV-
H3HA immunizations did not survive, lungs from dead
mice in these groups had to be selected to test for viral
titers. As expected, the mice of the pVAX1 control
group and pV-H3HA group all had positive viral titers
in the lung. By contrast, no measurable virus titers were
detected in the lungs in the multi-epitope immunized
group, and somewhat lower levels of virus (expressed as
plaque forming units, or PFU) were observed in the pV-
H3-H1 and pV-H1HA1 immunized groups (Figure 8).
Discussion
In light of the recent 2009 H1N1 pandemic, there is an
urgent need to develop new influenza vaccines. New
influenza vaccines should have the following characteris-
tics: low cost, high level immunogenicity, rapid prepara-
tion, protection against rapid virus mutation and long-
term protection against multiple subtypes of influenza,
especially against potential influenza pandemic strains.
The purpose of this study was to further develop and
evaluate a novel approach to vaccination based on
Figure 3 Immunofluorescence assays to detect antigens expressed from the HA-based DNA vaccine by immune sera.( A )p V - H 3 H A
detected by H3+ serum, (B) pV-H1HA1 detected by H1+ serum, (C) pV-H3-H1 detected by H3+ serum, (D) pV-H3-H1 detected by H1+ serum, (E)
pV-H3-EHA-H1 detected by H3+ serum, (F) pV-H3-EHA-H1 detected by H1+ serum, (G) pV-H3-EHA-H1 detected by H5+ serum. (H) pV-H3-EHA-H1
detected by H7+ serum, (I) pV-H3-EHA-H1 detected by H9+ serum, (J) pVAX1 control group. The BHK cells transfected with recombinant
plasmids displayed specific fluorescence at the cell membrane and throughout the cytoplasm, while those transfected with the empty pVAX1
vector control were negative.
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Page 7 of 13Figure 4 IFN-g (Th1) and IL-4 (Th2) cytokine levels in serum samples. (A) IFN-g secretions of the immunized groups were significant higher
than that of the control pVAX1 group (P < 0.01) but were not significantly different from each other (P > 0.05). (B) The IL-4 level of the multi-
epitope vaccine group was significantly higher than the other 3 groups (P < 0.05). These data represent 3 repeated cytokine measurements.
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Page 8 of 13Figure 5 Cellular immune responses in vaccinated mice. Specific responses of splenocytes taken 14 days after the second boost were
determined by the IFN-g ELISpot assay with stimulation from (A) A/New Caledonia/20/99 (H1N1) and A/Wisconsin/67/2005 (H3N2) inactivated
whole virus, and (B) influenza H5, H7 and H9 subtype specific peptides. Upon stimulation with the H7 and H9 subtype epitope peptides, the
splenocytes from the multi-epitope DNA vaccine pV-H3-EHA-H1 showed significantly higher responses than other immunized groups (P < 0.05).
Data are presented as mean ± SD of five mice per group. SFC, spot forming cells.
Tan et al. Virology Journal 2010, 7:363
http://www.virologyj.com/content/7/1/363
Page 9 of 13multi-subtype influenza epitopes using mice as a mam-
malian model. We assessed the immunogenicity of an
H3/H1-derived multi-epitope DNA vaccine and its pro-
tective efficacy against H1N1 virus challenge. The
experiment was set up to systematically compare the
specially designed multi-epitope vaccine with the sepa-
rate antigen components of the immunized groups and
a control group.
The MHC II molecule pathway of antigen processing
is first activated in an APC by phagocytosis, pinocytosis,
or receptor-mediated endocytosis of an exogenous anti-
gen. The phagocytic lysosome products are digested into
linear epitopes and then later associated with MHC II
molecules to be presented on the surface of the APC.
Th cells and APC recognition between cells and signal
transduction and the resulting induced Th cell activa-
tion play an important role in the initiation of an
acquired immune response, maintenance of responses in
chronic infections and development of immune
memory. Activated Th cells produce cytokines that can
effectively regulate cytotoxic T cells, B cells and phago-
cytic cell functions [20].
B cell epitopes form the basis of humoral immunity in
that they determine the specificity of antibodies. B cells
can capture antigens through the BCR and function as
APC to activate Th cells. Activated Th cells can also
activate B cells in turn to produce antibodies against the
corresponding antigen. An ideal immunogenic epitope is
one that elicits responses from both Th and B cells [21].
Therefore, the purpose of this study was to design a
vaccine with a minimal set of epitopes that are predicted
to cross-stimulate both Th and B cell subsets.
IFN-g is the defining Th1 type cytokine, with impor-
tant immunoregulatory functions including the ability to
activate macrophages, induce monocyte cytokine secre-
tion, affect the body’s Th1/Th2 balance, regulate antigen
presenting cells, and significantly increase MHI-1 and
MHC-II molecule expression [22]. IL-4 is the
Figure 6 Humoral immune responses in vaccinated mice. ELISAs to detect virus-specific IgG antibodies were performed utilizing plates
coated with (A) A/Wisconsin/67/2005 (H3N2), (B) A/New Caledonia/20/99 (H1N1), or (C) influenza standard antigens of H5, H7, H9 subtypes. Data
shown are mean antibody titers of five mice in each group with coefficients of variations (error bars). The differences in titers between
experimental groups and the negative control group (pVAX1) were statistically significant (P < 0.01). However, the differences in the responses
against the H3N2 and H1N1 antigens in the ELISA between the multi-epitope pV-H3-EHA-H1 and pV-H3 and between pV-H1 and pV-H3-H1
groups were not significant (P > 0.05). With the H5, H7 and H9 standard antigens as the coated proteins in the ELISA, the responses in the
pV-H3-EHA-H1 group were significantly higher than those of the other vaccine groups at 35 DPI (P < 0.05).
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Page 10 of 13Figure 7 Survival of immunized mice from lethal dose challenge of H1N1 virus.G r o u p so f1 0m i c ew e r ei m m u n i z e dI Mw i t ht h e
recombinant vaccines (striped lines) or with the pVAX1 vector control (solid line). The schedule of administration was 2 times with a 3-week
interval, and the challenge with 10 LD50 of influenza virus (A/New Caledonia/20/99 (H1N1)) was given 2 weeks after the boost. A significant
difference (P < 0.05) in survival was observed between multi-epitope group pV-H3-EHA-H1 (100%) and pV-H3 (20%), but no significant difference
was found compared to the pV-H1HA1 (90%) and pV-H3-H1 (80%) groups (P > 0.05).
Figure 8 Viral lung titers in immunized animals. Five weeks after immunization with pV-H3-EHA-H1, pV-H3HA, pV-H3-H1, pV-H1HA1 or pVAX1
control, protection of mice from intranasal challenge with 10 LD50 A/New Caledonia/20/99 (H1N1) was determined by detection of viral titers in
the lung using a plaque formation assay on MDCK cells. Log10 values of the mean titer for each group are shown.
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Page 11 of 13representative Th2 type cytokine, with the ability to pro-
mote B cell proliferation and antibody production [23].
In this study, we examined these two cytokines to evalu-
ate the immune bias induced by the multi-epitope vac-
cine. Our analyses revealed that the IFN-g level of the
multi-epitope vaccine immunized group was the highest,
indicating effective stimulation of the Th1 response,
although it was not significantly different from the other
three vaccine groups (P > 0.05). However, the stimula-
tion of IL-4 levels by the multi-epitope vaccine was sig-
nificantly higher than the other vaccine groups (P <
0.05), indicating that the multi-epitope pV-H3-EHA-H1
vaccine could enhance Th2 cell immune function.
Therefore, the multi-epitope vaccine tended to induce a
dominant Th2 response which could then promote
humoral immune responses.
Production of antibodies against viral infection is an
important effector function, and the level of humoral
immunity reflects the ability and strength of the body to
block infection, to rid itself of the virus if infection
occurs, or at least to prevent tissue damage [24]. In per-
spective, the four DNA vaccines were effective in stimu-
lating specific antibodies against the major antigens
from the H3 and H1 subtypes of influenza in mice. Spe-
cific antibody levels increased with the number of
immunizations, rapidly rising after the boost immuniza-
tion. At 35 DPI, the multi-epitope immunization group
had virus-specific antibody levels equivalent to the H1
and H3 immune groups, suggesting that the epitopes
induced by the structural HA antigen is still a major
determinant of specific antibody production. From ana-
lyzing the virus-specific IgG epitopes associated with
H5, H7, H9 subtypes of influenza, the multi-epitope
immunized group showed advantages compared with
the pV-H1HA1, pV-H3HA and pV-H3-H1 groups (P <
0.05), which confirmed that epitopes in a multi-epitope
vaccine could induce functional antibodies, especially
those of the H5 subtype.
The DNA vaccines also effectively stimulated cellular
immune responses in mice as evaluated by the IFN-g
ELISpot assays. For the H3 and H1 IFN-g responses, the
multi-epitope group produced the highest number of
spots, but not significantly different compared with the
single antigen expressing and the dual antigen expres-
sing groups (P > 0.05). When stimulated with peptides
associated with the H5, H7, H9 antigens, the splenocytes
of the multi-epitope vaccine group produced the highest
number of IFN-g spots which was significantly different
from that of the other groups. Together these results
indicate that the HA subtype and the specific epitopes
may play major roles in inducing Th1 cellular immune
responses.
Further evidence of the efficacy of the multi-epitope
vaccine was provided by the in vivo challenge studies.
These protection experiments showed differences in the
morbidity of the animals as well as a statistically signifi-
cant difference between the survival curves of the vacci-
nated groups and the pVAX1 control groups. The
multi-epitope group showed 100% protection against
lethal challenge, but it was not significantly different
compared to the pV-H1HA1 and pV-H3-H1 groups (P
> 0.05). No measurable virus titers were detected in the
lungs of the mice in the multi-epitope immunized
group. Somewhat lower virus titers were observed in the
pV-H3-H1 and pV-H1HA1 groups, which indicated that
the constituent epitopes contributed to the cross-protec-
tive immunity against H1N1 viral challenge.
Conclusion
Overall, the multi-epitope DNA vaccine induced signifi-
cant levels of humoral and cellular responses as well as
provided cross-protective immunity. This study demon-
strates the proof-of-principle that a universal DNA vac-
cine with engineered epitopes may protect against
multiple subtypes of influenza virus, afford long-term
immune protection, and prevent cross-species
transmission.
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